Financial & Business, OEM News

Bausch + Lomb Buys Elios Vision to Boost Glaucoma Treatment

Elios Vision is the developer of the ELIOS procedure, a minimally invasive glaucoma surgery procedure that uses an excimer laser.

Author Image

By: Sam Brusco

Associate Editor

Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure that uses an excimer laser.

This deal allows new opportunities to treat glaucoma in conjunction with cataract surgery without implants. It also bolsters Bausch + Lomb’s glaucoma portfolio, which already contains pharmaceutical and surgical approaches.

“Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040.”

Compared to other glaucoma surgery techniques, MIGS provides a safe, effective approach to reducing intraocular pressure with quicker recovery time. It can be done in tandem with cataract surgery—over 19% of patients needing cataract surgery also have glaucoma or ocular hypertension.1

“ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma,” said Professor Ike K. Ahmed, MD, University of Toronto and Moran Eye Center. “The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quality of life.”

The ELIOS technology is CE marked and currently sold in the EU. Elios Vision is in the process of pursuing U.S. Food and Drug Administration (FDA) approval for the product.

“Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help change the treatment paradigm for the estimated 80 million people worldwide living with glaucoma,” said Elliot Friedman, former Elios Vision chairman and CEO. “The goal is to make combining cataract and glaucoma treatment the new standard of care, and that’s even more attainable given Bausch + Lomb’s presence in nearly 100 countries.”

Reference
1 Tseng, VL, Yu, F, et al. JAMA. 2012 Aug. 1.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics